Friday, November 06, 2020 1:42:22 PM
I have not read the paper (see abstract below) but, if the authors are correct, I suppose a master trader could try and sell some calls here. I'm not a trader so I won't try.
"Abstract We examine stock price movements,around the announcement,and implementation,of changes in the S&P MidCap 400 and S&P SmallCap 600 indices. For both promotions to and demotions from the indices, we find significant movements in the price of stocks facing a status change on both on the trading day following the announcement,and the trading day leading up to the implementation. The stock price change is positive for promotions and negative for demotions. Although part of this price movement,is retraced in the trading days after the implementation of the change, about half to three-quarters of the movement,is permanent. 1. Introduction. The last thirty years have seen the rise of equity index investing, driven primarily by a"
https://www.researchgate.net/publication/228384346_Stock_Price_Effects_of_Changes_in_the_SP_MidCap_400_and_the_SP_SmallCap_600_Indices
"Abstract We examine stock price movements,around the announcement,and implementation,of changes in the S&P MidCap 400 and S&P SmallCap 600 indices. For both promotions to and demotions from the indices, we find significant movements in the price of stocks facing a status change on both on the trading day following the announcement,and the trading day leading up to the implementation. The stock price change is positive for promotions and negative for demotions. Although part of this price movement,is retraced in the trading days after the implementation of the change, about half to three-quarters of the movement,is permanent. 1. Introduction. The last thirty years have seen the rise of equity index investing, driven primarily by a"
https://www.researchgate.net/publication/228384346_Stock_Price_Effects_of_Changes_in_the_SP_MidCap_400_and_the_SP_SmallCap_600_Indices
Recent HALO News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/15/2026 08:13:30 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/11/2026 08:10:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/11/2026 08:09:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/11/2026 08:06:06 PM
- HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE • PR Newswire (US) • 05/11/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 11:04:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 11:04:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 11:03:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 11:02:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 11:02:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 11:01:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:16:24 PM
- Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets • PR Newswire (US) • 05/07/2026 01:00:00 PM
- Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology • PR Newswire (US) • 05/06/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/05/2026 09:05:10 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/01/2026 08:45:44 PM
- Halozyme to Report First Quarter 2026 Financial and Operating Results • PR Newswire (US) • 04/30/2026 08:30:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/30/2026 02:39:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 12:12:51 PM
- Halozyme Appoints Darren Snellgrove as Chief Financial Officer • PR Newswire (US) • 04/30/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/24/2026 08:06:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/07/2026 09:13:42 PM
- Halozyme signs licensing deal with Vertex for drug delivery technology • IH Market News • 04/07/2026 02:11:29 PM
- Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology • PR Newswire (US) • 04/07/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:29:18 PM
